Pliant Therapeutics, Inc.

PLRX

US7291391057

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
13.41 ^USD	-2.76%		+5.92%	-25.95%

05-07	Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating	MT
05-07	RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk	MT

Pliant Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023

August 09, 2023 at 09:03 pm

Pliant Therapeutics, Inc. reported earnings results for the second quarter ended June 30, 2023. For the second quarter, the company reported sales was USD 0.248 million compared to USD 4.99 million a year ago. Net loss was USD 41.19 million compared to USD 29.55 million a year ago.

Basic loss per share from continuing operations was USD 0.7 compared to USD 0.82 a year ago.

Latest news about Pliant Therapeutics, Inc.

Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating	05-07	MT
RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk	05-07	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	03-12	CI
RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	03-05	MT
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk	02-28	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating	02-06	MT
Transcript : Pliant Therapeutics, Inc. - Special Call	02-05
HC Wainwright Adjusts Pliant Therapeutics Price Target to $48 From $52, Maintains Buy Rating	02-05	MT
Pliant Therapeutics Reports Interim 'Positive' Safety, Efficacy Data for Potential Liver Disease Drug	02-05	MT
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	02-04	CI
Pliant Therapeutics Insider Sold Shares Worth $443,173, According to a Recent SEC Filing	01-19	MT
Top Premarket Decliners	01-11	MT
Transcript : Pliant Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	01-09
RBC Trims Price Target on Pliant Therapeutics to $53 From $54, Keeps Outperform, Speculative Risk	11-10	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Pliant Therapeutics Appoints Chief Regulatory Officer	16/10/23	MT
Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer	16/10/23	CI
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $52 From $50, Maintains Buy Rating	27/09/23	MT
Transcript : Pliant Therapeutics, Inc. - Special Call	26/09/23
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	26/09/23	CI
Pliant Therapeutics to Discuss Interim Results Phase 2a Primary Sclerosing Cholangitis Trial Tuesday; Shares Surge Premarket	26/09/23	MT
Pliant Therapeutics to Discuss Interim Results From Phase 2a Primary Sclerosing Cholangitis Trial Tuesday; Shares Surge After-Hours	25/09/23	MT
Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer	15/09/23	CI

Chart Pliant Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of Î±vÃ6 and Î±vÃ1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of Î±vÃ1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of Î±vÃ8 and Î±vÃ1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Sector

Pharmaceuticals

Calendar

14/05/2024 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Pliant Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.41 USD

Average target price

41.08 USD

Spread / Average Target

+206.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PLIANT THERAPEUTICS, INC.	-25.95%	809M
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	328B
ABBVIE INC.	+3.54%	283B
ASTRAZENECA PLC	+15.70%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+6.70%	165B

Other Pharmaceuticals